文献速递哮喘

度普利尤单抗减少激素依赖性重度哮喘患者口服糖皮质激素使用:TRAVERSE开放标签扩展研究分析

Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
PubMed 文献 · Chest · 2022-02-22

结果显示两组口服糖皮质激素(OCS)剂量自VENTURE基线持续下降,至TRAVERSE第96周分别降至1.2 mg/d和3.0 mg/d(较基线下降89.3%和74.4%),急性发作率低,FEV1和ACQ-5评分进一步改善,安全性符合已知特征。

要点

  • 度普利尤单抗可持续维持OCS减量,第96周dupilumab/dupilumab组OCS降至1.2 mg/d,较VENTURE基线下降89.3%。
  • 安慰剂转为度普利尤单抗组第96周OCS降至3.0 mg/d,较VENTURE基线下降74.4%。
  • TRAVERSE期间急性发作率低,FEV1和ACQ-5评分较VENTURE进一步改善。

核心结论

  • 在开放标签TRAVERSE研究中,度普利尤单抗能够维持母体OCS减量研究中的OCS剂量下降,同时保持低急性发作率和肺功能改善。

研究设计与样本

  • LIBERTY ASTHMA TRAVERSE(NCT02134028)为多国、多中心、单臂、开放标签扩展研究,纳入≥12岁既往参与度普利尤单抗研究的哮喘患者。
  • 治疗为度普利尤单抗300 mg每2周一次,最长96周。

主要发现

  • VENTURE基线时平均OCS剂量为dupilumab组11.0 mg/d、安慰剂组11.6 mg/d。
  • TRAVERSE第0周平均每日OCS剂量在dupilumab/dupilumab组为3.1 mg/d、placebo/dupilumab组为6.4 mg/d,较VENTURE基线分别下降68.8%和41.3%。
  • TRAVERSE第48周OCS剂量分别降至2.2 mg/d和4.9 mg/d(较VENTURE基线下降78.3%和53.4%),第96周降至1.2 mg/d和3.0 mg/d(下降89.3%和74.4%)。
  • TRAVERSE研究期间急性发作率低,FEV1和5项哮喘控制问卷(ACQ-5)评分较VENTURE进一步改善。
  • 安全性发现与度普利尤单抗已知安全性特征一致。

临床怎么用

  • 对于OCS依赖性重度哮喘患者,度普利尤单抗可作为长期维持OCS减量的治疗选择,并在扩展治疗中持续获益。

局限性

  • 本研究为单臂、开放标签扩展研究,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with severe asthma require chronic corticosteroid treatment to maintain asthma control. RESEARCH QUESTION: Are the reduction in oral corticosteroid (OCS) use and the clinical efficacy observed with dupilumab treatment maintained long-term in patients with severe OCS-dependent asthma? STUDY DESIGN AND METHODS: The LIBERTY ASTHMA TRAVERSE study (ClinicalTrials.gov identifier: NCT02134028) was a multinational, multicenter, single-arm, open-label extension study in patients ≥ 12 years of age with asthma who participated in previous dupilumab studies. Treatment consisted of dupilumab 300 mg every 2 weeks for up to 96 weeks. In this analysis, we present the data from patients who initially enrolled in the LIBERTY ASTHMA VENTURE study (ClinicalTrials.gov identifier: NCT02528214), a 24-week placebo-controlled study of dupilumab in patients with OCS-dependent severe asthma, and continued in the TRAVERSE study. The subgroups analyzed were: those who received dupilumab in both (dupilumab/dupilumab group) and those who received placebo in the VENTURE study and dupilumab in the TRAVERSE study (placebo/dupilumab group). Outcomes included OCS use, exacerbation rates, and measures of lung function and asthma control. RESULTS: Ninety patients treated with dupilumab/dupilumab and 97 patients treated with placebo/dupilumab in the VENTURE study were enrolled and treated in the TRAVERSE study, with a mean OCS dosage of 11.0 mg/d (dupilumab) and 11.6 mg/d (placebo) at VENTURE study baseline. At TRAVERSE week 0, the mean daily OCS dosage was 3.1 mg/d and 6.4 mg/d (percentage decrease from the VENTURE study baseline, 68.8% and 41.3%) for the dupilumab/dupilumab group and placebo/dupilumab group, respectively, and decreased to 2.2 mg/d and 4.9 mg/d (78.3% and 53.4%) at week 48 and to 1.2 mg/d and 3.0 mg/d (89.3% and 74.4%) at week 96, respectively. Exacerbation rates were low during the TRAVERSE study. Further improvements from the VENTURE to TRAVERSE studies also were seen in FEV1 and 5-item Asthma Control Questionnaire scores. Safety findings were consistent with the known dupilumab safety profile. INTERPRETATION: In the open-label TRAVERSE study, dupilumab demonstrated the ability to sustain the OCS dosage reduction from the parent OCS-sparing study, while maintaining a low exacerbation rate and improved lung function. TRIAL REGISTRY: ClinicalTrials.gov; Nos.: NCT02134028 (TRAVERSE) and NCT02528214 (VENTURE); URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Sher LD, Wechsler ME, Rabe KF, et al. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest. 2022. PMID: 35217003. doi:10.1016/j.chest.2022.01.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。